Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00281073 · ClinicalTrials.gov registry record · Phase 1

Intra-Cardiac Echocardiography Guided Cardioversion(ICE-CHIP) Study

A Phase 1 study of Atrial Fibrillation, sponsored by EP MedSystems.

Completed
Registry status
Phase 1
Development phase
95
Enrollment target
6
Study locations

NCT00281073: Completed Phase 1 study of Atrial Fibrillation, sponsored by EP MedSystems.

NCT00281073 is a Phase 1 study of Atrial Fibrillation that has completed, run by EP MedSystems. The registered enrollment target is 95 participants, below the 2,996-participant average among 202 other Atrial Fibrillation trials with a reported enrollment target (97% lower). The trial reports 6 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00281073, a Phase 1 study of Atrial Fibrillation, has completed, sponsored by EP MedSystems.

COMPLETED
Registry status
Phase 1
Development phase
95 participants
Enrollment target
6
Study locations

Study Summary

This is a sequential phase 1 and phase 2 study to evaluate the efficacy of intracardiac echocardiography to detect septal and left atrial pathology as compared to transesophageal echocardiography (Phase 1) and its value in a management strategy for immediate cardioversion during cardiac catheterization procedures in patients with atrial fibrillation as compared to a conventional strategy delaying cardioversion till full anticoagulation is established for a three weeks (Phase 2). Phase 1 will enroll 100 patients at 12 centers; these patients will be undergoing clinically indicated TEE \& cardiac catheterization procedures. After review of Phase 1 results by an independent DSMB \& the investigators that establish efficacy of ICE, Phase 2 will be initiated. Phase 2 will enroll 300 patients in 15 centers; these patients with atrial fibrillation will be undergoing clinically indicated cardiac catheterization procedures and have a clinical indication for cardioversion. Patients will be randomized to ICE guided cardioversion strategy or a conventional strategy employing three weeks of full anticoagulation before cardioversion. ICE imaging will be used to identify a low risk group for immediate cardioversion. A composite primary study endpoint that will include mortality and major morbidity including stroke and bleeding complications will be used. This study will examines two hypotheses in AF patients undergoing invasive cardiac procedures: Hypothesis 1: That ICE has comparable efficacy to TEE in visualization of left atrial pathology or septal defects that can predispose patients to stroke. This will be evaluated during the Phase I component of the study. Hypothesis 2: That ICE can identify low risk patients in whom immediate cardioversion during the procedure is safe and comparably effective to electrical cardioversion performed based on a conventional strategy of a minimum of 3 weeks of preceding anticoagulation therapy. Low risk patients are expected to have an accep

Primary Outcome

Prevalence of thrombi or spontaneous contrast detected by ICE

Conditions Studied

Atrial Fibrillation

Interventions

  • DEVICE Intra-Cardiac Echocardiography guided Cardioversion
  • DEVICE Intracardiac Echo
  • DEVICE ICE

Study Locations (6)

Illinois

  • University of Chicago - Center for Advanced Medicine - Chicago
  • Carle Clinic - Urbana

Florida

  • Mayo Clinic - Jacksonville

Ohio

  • Cleveland Clinic Foundation - Cleveland

Wisconsin

  • Aurora Sinai Medical Center / St. Lukes Medical Center - Milwaukee

Rotterdam

  • Erasmus University Medical Center - Rotterdam

Trial Details

FieldValue
Enrollment Target 95 participants
Start Date 2005-03
Est. Completion 2008-07
Phase Phase 1
EP MedSystems

1 total trials

What the finished NCT00281073 record still lists

NCT00281073 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 95 participants, a relatively small participant target, below the 2,996-participant average among 202 other Atrial Fibrillation trials with a reported enrollment target (97% lower).

The record links to 1 condition, with Atrial Fibrillation appearing as the primary indexed condition, and to 3 interventions - of which Intra-Cardiac Echocardiography guided Cardioversion is the first listed.

NCT00281073 lists 6 locations in 5 states (Illinois, Florida, Ohio).

Frequently Asked Questions

What is clinical trial NCT00281073 about?

NCT00281073 is a clinical study titled "Intra-Cardiac Echocardiography Guided Cardioversion(ICE-CHIP) Study". This is a sequential phase 1 and phase 2 study to evaluate the efficacy of intracardiac echocardiography to detect septal and left atrial pathology as compared to transesophageal echocardiography (Phase 1) and its value in a management strategy for immediate cardioversion during cardiac catheterizat...

What is the current status of trial NCT00281073?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 95 participants. The study started on 2005-03. Estimated completion is 2008-07.

What conditions does trial NCT00281073 study?

This clinical trial studies the following conditions: Atrial Fibrillation.

What interventions are being tested in trial NCT00281073?

The interventions under investigation include: Intra-Cardiac Echocardiography guided Cardioversion (DEVICE), Intracardiac Echo (DEVICE), ICE (DEVICE).

Who is sponsoring clinical trial NCT00281073?

This trial is sponsored by EP MedSystems, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00281073 being conducted?

This trial has 6 study locations across Florida, Illinois, Ohio, Wisconsin, Rotterdam. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Atrial Fibrillation

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00281073's enrollment target sits among peer trials

95 145th of 202 higher than 58 of 202 other Atrial Fibrillation trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Atrial Fibrillation trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03339128 · 95 participants · Phase 2

    Study to Explore the Therapeutic Effect of Eluxadoline in Treating Irritable Bowel Syndrome With Diarrhea in Children

  • NCT03509961 · 95 participants · Phase 2

    The EndRAD Trial: Eliminating Total Body Irradiation (TBI) for NGS-MRD Negative Children, Adolescents, and Young Adults With B-ALL

  • NCT03694756 · 95 participants · NA

    TMEM-MRI: A Pilot Feasibility Study of MRI for Imaging of TMEM in Patients With Operable Breast Cancer

  • NCT04206215 · 95 participants · NA

    Noninvasive Brain Stimulation for Treating Carpal Tunnel Syndrome

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Related registry views

Source: ClinicalTrials.gov NCT00281073, the US trial registry maintained by the National Library of Medicine. NCT00281073 (small enrollment · multi site footprint · completed) retrieved and formatted by PlainTrial, see methodology.